Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
- PMID: 32887684
- DOI: 10.1136/annrheumdis-2020-218276
Management of immune checkpoint inhibitor-induced polymyalgia rheumatica
Keywords: autoimmunity; glucocorticoids; polymyalgia rheumatica.
Conflict of interest statement
Competing interests: KSMvdG and EB as employees of the UMCG received speaker/consulting fees from Roche that were paid to the UMCG. TJNH as employee of the UMCG received sponsoring/research fee/advisory board fee/other income from BMS, AZD, Merck, Boehringer, Pfizer, Eli Lilly, Roche, Platform immunotherapy and CANCER-ID. SFO received research grants from Novartis and Celldex, paid to the institution.
Comment on
-
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
